

WOAH Reference Laboratory Reports Activities 2023

Activities in 2023

This report has been submitted : 13 juin 2024 11:33

Laboratory Information

Name of disease (or topic) for which you are a designated WOAHO Reference Laboratory:	Peste equina africana
Address of laboratory:	LCV Ctra M106, Km 1,4 28110, Algete, Madrid, España; UCM Avda. Puerta de Hierro s/n 28040 Madrid, España
Tel.:	(LCV) 0034913478312 ; (UCM) 0034913944082
E-mail address:	(LCV) maguerog@mapa.es; (UCM) jmvizcaino@ucm.es
Website:	(LCV) https://www.mapa.gob.es/es/ganaderia/temas/laboratorios/referencia-union-europea-oie/
Name (including Title) of Head of Laboratory (Responsible Official):	(LCV) Dr. Montserrat Agüero; (UCM) Prof. Jose Manuel Sánchez Vizcaíno
Name (including Title and Position) of WOAHO Reference Expert:	(LCV) Dr. Montserrat Agüero; (UCM) Prof. Jose Manuel Sánchez Vizcaíno
Which of the following defines your laboratory? Check all that apply:	Governmental Academic institution

TOR1: DIAGNOSTIC METHODS

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in WOAHO Manual (Yes/No)	Total number of test performed last year	
		Nationally	Internationally
Indirect diagnostic tests			
(LCV) ELISA bloqueo		552	14
Direct diagnostic tests			
(LCV) RRT-PCR Agüero et al; 2008 (VP7)		360	10
(LCV) RRT-PCR multiplex específicas de serotipo (VP2)		0	30

TOR2: REFERENCE MATERIAL

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by WOAHO?

No

3. Did your laboratory supply standard reference reagents (nonWOAH-approved) and/or other diagnostic reagents to WOAHO Members?

Yes

TYPE OF REAGENT AVAILABLE	RELATED DIAGNOSTIC TEST	PRODUCED/ PROVIDE	AMOUNT SUPPLIED NATIONALLY (ML, MG)	AMOUNT SUPPLIED INTERNATIONALLY (ML, MG)	NO. OF RECIPIENT WOAHO MEMBER COUNTRIES	COUNTRY OF RECIPIENTS
						AUSTRIA, BELGIUM, BULGARIA, CANADA,

<p>(LCV)VPEA de los serotipos 2, 8 y 9 inactivados. Enviados en el ensayo de intercomparación organizado por el EU-RL</p>	<p>RT-PCR</p>	<p>20 ml/virus inactivado</p>	<p>600µl/muestra (10 muestras/participante)</p>	<p>600µl/muestra (10 muestras/participante)</p>	<p>35</p>	<p>CZECH REPUBLIC, DENMARK, FINLAND, FRANCE, GERMANY, GREECE, HUNGARY, IRELAND, ITALY, KOREA (DEM. PEOPLE'S REP. OF), LATVIA, LITHUANIA, MALAYSIA, MOROCCO, POLAND, PORTUGAL, ROMANIA, SAUDI ARABIA, SERBIA, SLOVAKIA, SLOVENIA, SOUTH AFRICA, SPAIN, SWEDEN, SWITZERLAND, THAILAND, THE NETHERLANDS, TUNISIA, TURKEY, UNITED ARAB EMIRATES, UNITED KINGDOM,</p>
<p>(LCV) sueros equinos de animales vacunados frente al serotipo 4 del VPEA, de animales infectados naturalmente y experimentalmente y de caballos negativos enviados en el ensayo de intercomparación organizado por el EU-RL</p>	<p>ELISA</p>	<p>30 ml/suero</p>	<p>300µl/muestra (10 muestras/participante)</p>	<p>300µl/muestra (10 muestras/participante)</p>	<p>38</p>	<p>AFGHANISTAN, AUSTRIA, BELGIUM, BULGARIA, CANADA, CROATIA, CYPRUS, CZECH REPUBLIC, DENMARK, FINLAND, FRANCE, GERMANY, GREECE, HUNGARY, IRELAND, ITALY, KOREA (DEM. PEOPLE'S REP. OF), LATVIA, LITHUANIA, MALAYSIA, MALTA, MOROCCO, POLAND, PORTUGAL, ROMANIA, SAUDI ARABIA, SERBIA, SLOVAKIA, SLOVENIA, SOUTH AFRICA, SPAIN, SWEDEN, SWITZERLAND, THAILAND, THE NETHERLANDS, TUNISIA, TURKEY, UNITED ARAB EMIRATES, UNITED KINGDOM,</p>

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to WOAHA Members?

No

TOR3: NEW PROCEDURES

6. Did your laboratory develop new diagnostic methods for the designated pathogen or disease?

No

7. Did your laboratory validate diagnostic methods according to WOAHA Standards for the designated pathogen or disease?

No

8. Did your laboratory develop new vaccines for the designated pathogen or disease?

No
 9. Did your laboratory validate vaccines according to WOAH Standards for the designated pathogen or disease?

No
TOR4: DIAGNOSTIC TESTING FACILITIES

10. Did your laboratory carry out diagnostic testing for other WOAH Members?

Yes

NAME OF WOAH MEMBER COUNTRY SEEKING ASSISTANCE	DATE	WHICH DIAGNOSTIC TEST USED	NO. SAMPLES RECEIVED FOR PROVISION OF DIAGNOSTIC SUPPORT	NO. SAMPLES RECEIVED FOR PROVISION OF CONFIRMATORY DIAGNOSES
NIGERIA	2023-01-25	(LCV)ELISA	0	7
NIGERIA	2023-01-25	(LCV)RT-PCR	0	10

11. Did your laboratory provide expert advice in technical consultancies on the request of an WOAH Member?

No
TOR5: COLLABORATIVE SCIENTIFIC AND TECHNICAL STUDIES

12. Did your laboratory participate in international scientific studies in collaboration with WOAH Members other than the own?

Yes

Title of the study	Duration	PURPOSE OF THE STUDY	PARTNERS (INSTITUTIONS)	WOAH MEMBER COUNTRIES INVOLVED OTHER THAN YOUR COUNTRY
(LCV)"New RT-PCRs to detect AHSV"	2023-2024	Desarrollo y validación de una dúplex real time RT-PCR para la detección del VPEA	FLI (Alemania) OVI-ARC (Sudáfrica) LCV (España)	GERMANY SOUTH AFRICA SPAIN

13. In exercising your activities, have you identified any regulatory research needs* relevant for WOAH?

No
TOR6: EPIZOOLOGICAL DATA

14. Did your Laboratory collect epidemiological data relevant to international disease control?

No
 15. Did your laboratory disseminate epidemiological data that had been processed and analysed?

No
 16. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category and list the details in the box)

a) Articles published in peer-reviewed journals:

b) International conferences:

1
 AHS&BT EURL Annual meeting:
 - Rubén Villalba : "EURL AHS activities 2023"

c) National conferences:

d) Other (Provide website address or link to appropriate information):

1
(LCV)<https://www.mapa.gob.es/es/ganaderia/temas/laboratorios/referencia-union-europea-oie/>

TOR7: SCIENTIFIC AND TECHNICAL TRAINING

17. Did your laboratory provide scientific and technical training to laboratory personnel from other WOAH Members?

Yes

a) Technical visit : 0

b) Seminars : 0

c) Hands-on training courses: 1

d) Internships (>1 month) 0

Type of technical training provided (a, b, c or d)	Country of origin of the expert(s) provided with training	No. participants from the corresponding country
C	GREECE	1
C	CZECH REPUBLIC	1
C	IRELAND	1
C	LITHUANIA	1
C	MALTA	1
C	POLAND	1

TOR8: QUALITY ASSURANCE

18. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)	
(LCV) ISO 17025	Anexo Técnico Acreditación LCV_692_LE1530 Rev. 24 (20.05.24).pdf	Anexo Técnico Acreditación LCV_692_LE1530 Rev. 24 (20.05.24).pdf
(LCV) ISO 14001	CertificadoGA-2002-0327_ES_2023-11-03.pdf	CertificadoGA-2002-0327_ES_2023-11-03.pdf

19. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
(LCV) Detección de anticuerpos frente al VPEA mediante ELISA en sueros de équidos	ENAC
(LCV) Detección de orbivirus mediante cultivo celular (BTV, AHSV, EHDV) en muestras de sangre completa no coagulada, bazo, pulmón y nódulos linfáticos	ENAC
(LCV) Detección-identificación del VPEA mediante RT-PCR a tiempo real en muestras de vísceras de animales, sangre y cultivos celulares	ENAC
(LCV) Serotipificación de anticuerpos frente a Orbivirus por neutralización (BTV, AHSV,EHDV) en suero de rumiantes y équidos(LCV) Tipificación del VPEA mediante RT-PCR a tiempo real en muestras de vísceras de animales, sangre y cultivos celulares	ENAC
(LCV) Tipificación del VPEA mediante RT-PCR a tiempo real en muestras de vísceras de animales, sangre y cultivos celulares	ENAC

20. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

Yes

En el LCV hay un responsable de Bioseguridad y se dispone de procedimientos de identificación de peligros y evaluación de riesgo por patógeno y técnica. Además se dispone de los correspondientes procedimientos de trabajo

TOR9: SCIENTIFIC MEETINGS

21. Did your laboratory organise scientific meetings related to the pathogen in question on behalf of WOA?H?

No

22. Did your laboratory participate in scientific meetings related to the pathogen in question on behalf of WOA?H?

No

TOR10: NETWORK WITH WOA?H REFERENCE LABORATORIES

23. Did your laboratory exchange information with other WOA?H Reference Laboratories designated for the same pathogen or disease?

Yes

24. Do you network (collaborate or share information) with other WOA?H Reference Laboratories designated for the same pathogen?

Yes

NETWORK/DISEASE	ROLE OF YOUR LABORATORY (PARTICIPANT, ORGANISER, ETC)	NO. PARTICIPANTS	PARTICIPATING WOA?H REF. LABS
PEA	(LCV) Organizador	3	OVI-ARC(Sudáfrica) TPI (Reino Unido) LCV (España)

25. Did you organise or participate in inter-laboratory proficiency tests with WOA?H Reference Laboratories designated for the same pathogen?

Yes

PURPOSE OF THE PROFICIENCY TESTS: 1	ROLE OF YOUR REFERENCE LABORATORY (ORGANISER/ PARTICIPANT)	NO. PARTICIPANTS	PARTICIPATING WOA?H REF. LABS/ ORGANISING WOA?H REF. LAB.
(LCV) Ensayo interlaboratorial	Organizador y participante	47	OVI-ARC(Sudáfrica) TPI (Reino Unido) LCV (España)

26. Did your laboratory collaborate with other WOA?H Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

Yes

TITLE OF THE PROJECT OR CONTRACT	SCOPE	NAME(S) OF RELEVANT WOA?H REFERENCE LABORATORIES
Modificación de la real time RT-PCR descrita por Agüero et al; 2008 para la detección de nuevas cepas de PEA circulantes	Diagnóstico y control de la PEA	OVI-ARC(Sudáfrica) TPI (Reino Unido) LCV (España)

TOR11: OTHER INTERLABORATORY PROFICIENCY TESTING

27. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than WOA?H Reference Laboratories for the same pathogen?

Yes

Purpose for inter-laboratory test comparisons ¹	Role of your reference laboratory (organizer/participant)	No. participating laboratories	Name of the Test	WOA?H Member Countries
(LCV) Organización de un ensayo de intercomparación, como EU-RL, de aptitud para la evaluación de métodos de diagnóstico (detección de anticuerpos y genoma viral)	Organizador	47	XIX INTER-LABORATORY COMPARISON TEST FOR AFRICAN HORSE SICKNESS	AUSTRIA, BELGIUM, BULGARIA, CANADA, CROATIA, CYPRUS, CZECH REPUBLIC, DENMARK, FINLAND, FRANCE, GERMANY, GREECE, HUNGARY, IRELAND, ITALY, KOREA (DEM. PEOPLE'S REP. OF), LATVIA, LITHUANIA, MALAYSIA, MALTA, MOROCCO, POLAND, PORTUGAL, ROMANIA, SAUDI ARABIA, SERBIA, SLOVAKIA, SLOVENIA, SOUTH AFRICA, SPAIN, SWEDEN, SWITZERLAND, THAILAND, THE NETHERLANDS, TUNISIA, TURKEY, UNITED ARAB EMIRATES, UNITED KINGDOM,

TOR12: EXPERT CONSULTANTS

28. Did your laboratory place expert consultants at the disposal of WOA?H?

No

29. Additional comments regarding your report: